John McCamant photo


John McCamant


Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.

John's Articles

The long-awaited and overdue market rotation into biotech began last week, as the mega-tech trillion-dollar valuations finally receded. With bios languishing for the majority of the year, it didn’t take much to move our group and cause a breakout of the SPDR S&P Biotech ETF (XBI), observes John McCamant, editor of The Medical Technology Stock Letter.
Incyte Corp. (INCY) announced that it has entered into a definitive agreement to acquire Escient Pharmaceuticals (a private company) for $750 million. The company’s key drug development candidates include EP262, a first in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist, writes John McCamant, editor of The Medical Technology Stock Letter.
In a widely anticipated clinical trial in the blockbuster GLP class, Viking Therapeutics (VKTX) released excellent Phase I data for Oral ‘2735 at 28 days in obese patients, observes John McCamant, editor of The Medical Technology Stock Letter.
Viking Therapeutics (VKTX) shares recently soared when it released excellent Phase 2 SubQ data for VK2735 (GLP-1/GIP) showing treated patients lost up to 14.7% of their body weight over 13 weeks, in a clean, dose-dependent manner with high statistical significance (p<0.0001). The primary endpoint win is a 13.1 percentage point reduction in weight than the placebo group, explains John McCamant, editor of The Medical Technology Stock Letter.

John's Videos

Our recent recommendation of THRN, up 68%, was just the tip of the M&A iceberg as both Big Pharma and Big Bio have bulging war chests.

Biotech M&A results in overnight premiums of 50-200%. Find out how MTSL has discovered these biotech winners for our subscribers.
With hundreds of biotech companies to invest in, stock selection is paramount. In this session John will highlight past biotech winners to help frame current biotech recommendations.
John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.

Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More